REZOLUTE, INC. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- REZOLUTE, INC. stock issued during period, value, stock options exercised for the quarter ending 2026-06-30 was $250.00K, a 60.63% decline year-over-year.
- REZOLUTE, INC. stock issued during period, value, stock options exercised for the quarter ending 2026-03-31 was $749.00K, a 7390.00% increase year-over-year.
- REZOLUTE, INC. stock issued during period, value, stock options exercised for the quarter ending 2025-12-31 was $195.00K, a 70.36% decline year-over-year.
- REZOLUTE, INC. stock issued during period, value, stock options exercised for the quarter ending 2025-09-30 was $604.00K, a 549.46% increase year-over-year.
- REZOLUTE, INC. stock issued during period, value, stock options exercised for fiscal 2026 was $1.80M, a 28.80% increase from fiscal 2025.
- REZOLUTE, INC. stock issued during period, value, stock options exercised for fiscal 2025 was $1.40M, a 467.48% increase from fiscal 2024.
- REZOLUTE, INC. stock issued during period, value, stock options exercised for fiscal 2024 was $246.00K.
- REZOLUTE, INC. stock issued during period, value, stock options exercised for fiscal 2014 was $0.00.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-06-30 | $250.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-09-24 | $1.80M 10-K · filed 2026-09-24 |
| 2026-03-31 | $749.00K 10-Q · filed 2026-05-12 | $2.18M derived: sum of 4 quarters · filed 2026-09-24 |
| 2025-12-31 | $195.00K 10-Q · filed 2026-02-12 | $1.44M derived: sum of 4 quarters · filed 2026-09-24 |
| 2025-09-30 | $604.00K 10-Q · filed 2025-11-06 | $1.91M derived: sum of 4 quarters · filed 2026-09-24 |
| 2025-06-30 | $635.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-09-24 | $1.40M 10-K · filed 2026-09-24 |
| 2025-03-31 | $10.00K 10-Q · filed 2026-05-12 | $997.00K derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $658.00K 10-Q · filed 2026-02-12 | $997.00K derived: sum of 4 quarters · filed 2026-02-12 |
| 2024-09-30 | $93.00K 10-Q · filed 2025-11-06 | |
| 2024-06-30 | $236.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-09-17 | $246.00K 10-K · filed 2025-09-17 |
| 2024-03-31 | $10.00K 10-Q · filed 2025-05-13 | |
| 2014-06-30 | $0.00 10-K · filed 2015-09-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |